Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124136802 | 12413680 | 2 | F | 20160804 | 20160527 | 20160811 | EXP | US-SA-2016SA099723 | AVENTIS | EPSTEIN JB, GHARAPETIAN S, REJALI AR, ZABNER R, LILL M, TZACHANIS D. COMPLEX MANAGEMENT OF RESISTANT ORAL HERPES SIMPLEX VIRUS INFECTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: POTENTIAL ROLE OF TOPICAL CIDOFOVIR.SUPPORTIVE CARE IN CANCER. 2016; 24(8):3603-3606 | 67.00 | YR | A | M | Y | 0.00000 | 20160811 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124136802 | 12413680 | 1 | SS | FLUDARABINE PHOSPHATE. | FLUDARABINE PHOSPHATE | 1 | Unknown | UNKNOWN | 0 | ||||||||||
| 124136802 | 12413680 | 2 | PS | ANTI-THYMOCYTE GLOBULIN (RABBIT) | LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN | 1 | Unknown | U | UNKNOWN | 103869 | |||||||||
| 124136802 | 12413680 | 3 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 124136802 | 12413680 | 4 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 124136802 | 12413680 | 5 | SS | VALACICLOVIR | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | UNKNOWN | 0 | 1 | G | BID | |||||||
| 124136802 | 12413680 | 6 | SS | CYCLOSPORINE. | CYCLOSPORINE | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 124136802 | 12413680 | 7 | SS | MELPHALAN | MELPHALAN | 1 | Unknown | UNKNOWN | 0 | ||||||||||
| 124136802 | 12413680 | 8 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 124136802 | 12413680 | 9 | C | ACYCLOVIR. | ACYCLOVIR | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124136802 | 12413680 | 1 | Bone marrow conditioning regimen |
| 124136802 | 12413680 | 2 | Prophylaxis against graft versus host disease |
| 124136802 | 12413680 | 3 | Prophylaxis against graft versus host disease |
| 124136802 | 12413680 | 4 | Post transplant lymphoproliferative disorder |
| 124136802 | 12413680 | 5 | Antiviral treatment |
| 124136802 | 12413680 | 6 | Prophylaxis against graft versus host disease |
| 124136802 | 12413680 | 7 | Bone marrow conditioning regimen |
| 124136802 | 12413680 | 8 | Post transplant lymphoproliferative disorder |
| 124136802 | 12413680 | 9 | Antiviral prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124136802 | 12413680 | HO |
| 124136802 | 12413680 | OT |
| 124136802 | 12413680 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124136802 | 12413680 | Bronchopulmonary aspergillosis | |
| 124136802 | 12413680 | Campylobacter infection | |
| 124136802 | 12413680 | Candida infection | |
| 124136802 | 12413680 | Cytomegalovirus viraemia | |
| 124136802 | 12413680 | Disease progression | |
| 124136802 | 12413680 | Enterococcal bacteraemia | |
| 124136802 | 12413680 | Epstein-Barr viraemia | |
| 124136802 | 12413680 | Feeding disorder | |
| 124136802 | 12413680 | Herpes simplex | |
| 124136802 | 12413680 | Mouth ulceration | |
| 124136802 | 12413680 | Oral disorder | |
| 124136802 | 12413680 | Oral pain | |
| 124136802 | 12413680 | Post transplant lymphoproliferative disorder | |
| 124136802 | 12413680 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |